A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)
Active, no longer recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CheckMate 374
- Sponsors Bristol-Myers Squibb
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2016 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.
- 11 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2021.